Teva files new FDA petition against generic Copaxone

Teva Pharmaceutical Industries Ltd. has filed another citizen’s petition with the US Food and Drug Administration (FDA) against planned generic versions of its multiple sclerosis treatment Copaxone. On each of the previous seven occasions that Teva filed such a petition, the FDA ruled that it was too early to discuss such a matter.

The latest petition was filed at the end of last week in line with FDA instructions that any new Teva research data on Copaxone must be made public.